Trials / Recruiting
RecruitingNCT05689853
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
An Open-label, Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability and Antitumor Activity of AK119 in Combination With AK112 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 87 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase Ib/II study to assess the safety, tolerability and preliminary efficacy of AK119 combined with AK112 in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK119 | AK119 is an anti-CD73 monoclonal antibody. |
| DRUG | AK112 | AK112 is a bispecific monoclonal antibody against VEGF and PD-1. |
Timeline
- Start date
- 2023-04-14
- Primary completion
- 2026-12-01
- Completion
- 2027-06-01
- First posted
- 2023-01-19
- Last updated
- 2026-03-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05689853. Inclusion in this directory is not an endorsement.